Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia

Recruiting now

Conditions studied: Enterococcus Faecalis Infection, Blood Stream Infection, Gut Microbiomes

In brief

Prospective, multicenter, national, observational pharmacological study on the evaluation of efficacy of appropriate monotherapy vs combination treatment for non-complicated Enterococcus faecalis (EF) bloodstream infection (BSI) and identification of gut microbiota fingerprint of patients with EF-BSI correlated to antimicrobial treatment and clinical outcome

Key facts

Study ID

NCT06833593

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

510

Starts

2021-02-06

Expected to finish

2026-09-26

Last updated by the study team

2025-12-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult (≥18 years)
• Monomicrobial EF-BSI
• Receipt of ≥ 5 days of at least one in vitro active drug (ampicillin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin, vancomycin, teicoplanin, daptomycin and linezolid) with or without a synergistic drug (ceftriaxone, gentamycin, streptomycin), at common suggested dosages for EF-BSI in empirical or definitive therapy
• Written informed consent

You may not qualify if…

• Short term (within 3 days from BSI) mortality
• Other concomitant infection

Where it is running

• Ospedale Maggiore "Carlo Alberto Pizzardi" di Bologna — Bologna, Bologna, Italy (enrolling)
• IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Bologna, Italy (enrolling)
• Azienda Ospedaliero Universitaria di Catanzaro "Mater Domini" — Catanzaro, Catanzaro, Italy (enrolling)
• Humanitas Research Hospital — Milan, Milano, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.